Proper coordination between the newly established Pharmacovigilance Risk Assessment Committee and the other Committees of the Agency, in particular the Committee for Medicinal Products for Human Use, the Committee for Orphan Medicinal Products and the Committee for Advanced Therapies established under Regulation (EC) No 1394/2007 [OJ L 324, 10.12.2007, p. 121.] should be ensured.
Recital 28, Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…
In forcesince 15 Dec 2010